Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events

自2015年以来，我们一直是预防中心(第二周期，RFA-CK-18-001)的成员。我们的核心 调查小组在医疗保健相关感染和抗生素领域发表了430多份出版物 耐药性已被引用超过12,000次。我们核心项目的负责人已经有超过27个 作为首席研究人员的赠款和合同，并在科学专门知识领域发表了350多份出版物 在RFA里。自2015年以来，我们与目前的Eicenter II网站就53种出版物进行了合作，并 与目前的震中I网站合作出版了35种出版物。我们团队最大的优势之一是我们的 能够利用我们的经验和专业知识在现有客户之间完成协作项目 震中和其他医疗机构。我们提出具有创新性的核心和协作项目， 可行并响应疾控中心优先领域。 我们的核心建议是： 1.急性呼吸窘迫综合征呼吸机患者中鲍曼不动杆菌多重耐药的全州流行 长期设施。 2.院内菌血症和真菌血症监测在急诊中的使用和可用性评价 设施 3.减少养老院慢性呼吸机间多重耐药微生物的传播 4.评估在急性护理环境中采用有针对性的方法预防耐甲氧西林金黄色葡萄球菌接触的可行性 5.改进临床医生微生物学测试的解释和在所有医疗保健环境中的使用 我们的协作项目提案包括： 1.与急性护理环境中传播金黄色念珠菌有关的风险因素(大型项目) 2.呼吸机相关性肺炎的诊断管理：一项整群随机交叉试验 急性护理设施中的混合顺序审查和实验室报告干预(中型项目) 通过这些项目和其他合作项目的发展，我们期待着为 预防中心计划：保护患者免受感染、抗生素耐药性和其他疾病的影响 不良事件。

We have been a member of the Prevention Epicenters (Cycle II, RFA-CK-18-001) since 2015. Our core investigative group has over 430 publications in the area of healthcare-associated infections and antibiotic resistance which have been cited over 12,000 times. The leaders of our core projects have had more than 27 grants and contracts as principal investigators and have over 350 publications in the scientific expertise areas in the RFA. We have collaborated with the current Epicenter II sites on 53 publications since 2015 and have collaborated with current Epicenter I sites on 35 publications. One of our group’s greatest strengths is our ability to leverage our experience and expertise to complete collaborative projects among the existing Epicenters and other healthcare institutions. We propose core and collaborative projects that are innovative, feasible and responsive to CDC priority areas. Our core proposals are: 1. State-wide prevalence of multi-drug resistant Acinetobacter baumannii in ventilated patients in acute and long-term facilities. 2. Evaluation of use and usability of surveillance for hospital-onset bacteremia and fungemia in acute care facilities 3. Decreasing Transmission of Multi-drug Resistant Organisms in Chronic Ventilator Units in Nursing Homes 4. Assessing feasibility of a targeted approach to contact precautions for MRSA in the acute care setting 5. Improving clinician microbiology test interpretation and use in all healthcare settings Our collaborative project proposals are: 1. Risk factors associated with transmission of Candida auris in the acute care setting (Large Project) 2. Diagnostic Stewardship for Ventilator Associated Pneumonia: A cluster-randomized crossover trial of a hybrid order-review and laboratory reporting intervention in acute care facilities (Medium project) Through these projects and the development of other collaborative projects, we look forward to contributing to the Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance and Other Adverse Events.